Epithelial Ovarian Cancer

• CLINICAL_TRIALS withdrawal · 2025-09-23
  Clinical Trial Update: REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 [Phase 2, Phase 3]

  The REFRaME-O1 trial evaluating Luveltamab Tazevibulin versus investigator's choice chemotherapy for FOLR1-expressing ovarian cancer and rel…

• CLINICAL_TRIALS withdrawal · 2025-03-19
  Clinical Trial Update: A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer

  Pfizer's post-marketing surveillance study of Zirabev to assess safety and effectiveness in domestic cancer patients has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2025-02-21
  Clinical Trial Update: QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy [Phase 1, Phase 2]

  The QUILT-3.051 trial evaluating the NANT Ovarian Cancer Vaccine in epithelial ovarian cancer has been withdrawn in subjects who progressed …

• CLINICAL_TRIALS withdrawal · 2017-07-19
  Clinical Trial Update: Perioperative Assessment of Right Ventricular Function and Venous Return in Patients With Epithelial Ovarian Cancer Undergoing Cytoreductive Surgery (Gyn Right) - Pilot Study

  A pilot clinical trial evaluating perioperative assessment of right ventricular function and venous return in epithelial ovarian cancer pati…

• CLINICAL_TRIALS withdrawal · 2017-04-21
  Clinical Trial Update: N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer [Phase 1]

  A Phase 1 trial of intravenous N-acetylcysteine with cisplatin and paclitaxel for ovarian cancer has been withdrawn.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS withdrawal · 2014-08-11
  Clinical Trial Update: Influence of Chemotherapy on Gamma-delta T Cells in Patients With Epithelial Ovarian Cancer

  The clinical trial evaluating the impact of chemotherapy on gamma-delta T cells in epithelial ovarian cancer patients has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2013-12-18
  Clinical Trial Update: Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission [Phase 1, Phase 2]

  Withdrawal of a Phase 1/2 trial evaluating a cancer vaccine therapy in combination with the IDO1 inhibitor epacadostat (INCB024360) for epit…

• CLINICAL_TRIALS withdrawal · 2010-02-04
  Clinical Trial Update: Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel [Phase 1]

  A Phase 1 study evaluating AZD0530 (saracatinib) in combination with carboplatin and paclitaxel has been withdrawn, with conditions includin…